Advanced regenerative therapies. Clinical collaboration. Personalised health strategies.

InnaCell Therapeutics is a specialized distribution and consultancy company working at the intersection of clinical science and practical application.

Our role is to connect validated regenerative technologies with clinics, researchers, and individuals seeking evidence-informed health options.

Science-Driven Regeneration & Longevity

We collaborate with clinics and research institutes globally to:

Distribute

Provide access to advanced biological therapies

Consult

Design customised protocols for complex health conditions

Support

Support clinicians and researchers with technical and program development insight

Core Therapies

Our comprehensive suite of therapeutic products services caters to the growing need for advanced interventions

Small Mobile Cells

Universal transplant material to reverse fibrosis (e.g., COPD), neurodegenerative diseases, stroke recovery, sports injuries, longevity

Early Stem Cell Exosomes

Penetrate blood-brain/retina barriers; treat Parkinson’s, brain injury, stroke, CTE

Progenitor Cells & iPSCs

Organ-specific regeneration (kidney, heart, liver, retina); reversal of chronic organ failure

Gene Therapies (Non-Viral)

Non-integrative plasmid or mRNA delivery targeting longevity (Klotho), muscle rejuvenation (Follistatin), vascular health (VEGF)

Muse Cells

Circulate in blood to repair damaged tissue with minimal immune rejection

NK Cell-Derived Exosomes

Target mutated / cancerous / senescent cells; senolytic therapy; combined with plasmapheresis

Novel Peptides

Over 80 peptides targeting fibrotic conditions, mitochondrial health, CNS regeneration, reproductive health

Sublingual & Oral Peptides

Enhanced patient compliance with nanoparticle-based oral formulations avoiding injections

Learn More

Case Summaries

Case Review 1: Dementia

(90-year-old woman)

A case of a 90-year-old Caucasian female with progressive dementia, aphasia (non-verbal), hypertension, and type 2 diabetes.
Conclusion
- Protocol of MSC and MUSE exosomes demonstrated sustained cognitive and functional improvement in advanced dementia including recognition of family and verbalization of simple phrases.
Full details of interventions on Case Studies Page

Case Review 2: Multiple Sclerosis

(59-year-old woman)

A 59-year-old Caucasian woman diagnosed with MS at age 39, having failed all conventional treatments.
Conclusion
- Combination of MUSE exosomes, MUSE cells, and peptides produced major, sustained improvements across motor, sensory, visual, and cognitive domains, patient in remission.
Full details of interventions on Case Studies Page

Case Review 3: Rare Genetic Mutation

(33-year-old woman)

A 33-year-old woman with a rare genetic mutation.
Conclusion
- Multi-layered protocol with peptides and MUSE cells achieved sustainable remission and improvement in both pulmonary and renal function in an extremely rare condition.
Full details of interventions on Case Studies Page